 Peter Baker
Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Addison Disease | 5 | 2014 | 43 | 1.620 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 2 | 2020 | 22 | 1.330 |
Why?
| | Steroid 21-Hydroxylase | 4 | 2014 | 30 | 1.310 |
Why?
| | Metabolism, Inborn Errors | 2 | 2021 | 40 | 0.840 |
Why?
| | Ammonia | 1 | 2023 | 62 | 0.820 |
Why?
| | Adiposity | 2 | 2017 | 504 | 0.800 |
Why?
| | Glutathione | 1 | 2024 | 347 | 0.790 |
Why?
| | Autoantibodies | 6 | 2015 | 1467 | 0.780 |
Why?
| | Nutritional Status | 3 | 2023 | 328 | 0.770 |
Why?
| | Energy Metabolism | 3 | 2024 | 873 | 0.770 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2023 | 203 | 0.700 |
Why?
| | Leukodystrophy, Globoid Cell | 1 | 2020 | 8 | 0.690 |
Why?
| | Isoleucine | 1 | 2020 | 14 | 0.670 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 45 | 0.660 |
Why?
| | Obesity | 7 | 2018 | 2879 | 0.660 |
Why?
| | Valine | 1 | 2020 | 81 | 0.650 |
Why?
| | Fetal Macrosomia | 1 | 2020 | 62 | 0.650 |
Why?
| | Amino Acids | 4 | 2020 | 486 | 0.630 |
Why?
| | Epilepsy | 1 | 2023 | 322 | 0.630 |
Why?
| | Dietary Proteins | 1 | 2020 | 129 | 0.610 |
Why?
| | Dietary Supplements | 2 | 2020 | 534 | 0.600 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 110 | 0.600 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 260 | 0.590 |
Why?
| | Neonatal Screening | 1 | 2020 | 163 | 0.590 |
Why?
| | Mitochondria, Liver | 1 | 2018 | 74 | 0.590 |
Why?
| | Metabolomics | 3 | 2024 | 652 | 0.580 |
Why?
| | Neuroimaging | 1 | 2020 | 278 | 0.570 |
Why?
| | Kidney | 1 | 2024 | 1385 | 0.520 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 790 | 0.520 |
Why?
| | Liver | 2 | 2024 | 1839 | 0.520 |
Why?
| | Fatty Acids | 2 | 2017 | 427 | 0.500 |
Why?
| | Poland Syndrome | 1 | 2014 | 1 | 0.470 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 48 | 0.450 |
Why?
| | Birth Weight | 1 | 2017 | 505 | 0.450 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2014 | 78 | 0.450 |
Why?
| | HLA-B Antigens | 2 | 2011 | 62 | 0.450 |
Why?
| | Sequence Deletion | 1 | 2014 | 179 | 0.440 |
Why?
| | Acidosis, Lactic | 2 | 2024 | 46 | 0.440 |
Why?
| | Sulfurtransferases | 1 | 2013 | 9 | 0.440 |
Why?
| | Glutaredoxins | 1 | 2013 | 13 | 0.440 |
Why?
| | HLA-DR3 Antigen | 2 | 2012 | 80 | 0.440 |
Why?
| | Homocystinuria | 1 | 2014 | 70 | 0.430 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5439 | 0.430 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2013 | 51 | 0.420 |
Why?
| | Carnitine | 3 | 2020 | 76 | 0.420 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 820 | 0.400 |
Why?
| | Gene Expression | 1 | 2017 | 1466 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 7 | 2015 | 2276 | 0.400 |
Why?
| | Ring Chromosomes | 1 | 2010 | 4 | 0.350 |
Why?
| | Oxidative Stress | 4 | 2024 | 1266 | 0.350 |
Why?
| | Endocrine Cells | 1 | 2010 | 7 | 0.350 |
Why?
| | Carrier Proteins | 1 | 2014 | 742 | 0.340 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2515 | 0.340 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2015 | 3628 | 0.340 |
Why?
| | Abnormalities, Multiple | 2 | 2018 | 178 | 0.340 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 72 | 0.340 |
Why?
| | Muscle, Skeletal | 3 | 2019 | 1613 | 0.340 |
Why?
| | Mosaicism | 1 | 2010 | 71 | 0.330 |
Why?
| | Lipid Metabolism | 3 | 2018 | 497 | 0.320 |
Why?
| | Haplotypes | 4 | 2012 | 475 | 0.320 |
Why?
| | Male | 18 | 2024 | 63512 | 0.310 |
Why?
| | Face | 1 | 2010 | 165 | 0.310 |
Why?
| | Infant | 9 | 2024 | 8975 | 0.310 |
Why?
| | Autoimmunity | 2 | 2015 | 862 | 0.310 |
Why?
| | Genetic Variation | 1 | 2013 | 938 | 0.300 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3386 | 0.300 |
Why?
| | Biomarkers | 5 | 2024 | 3968 | 0.300 |
Why?
| | Humans | 29 | 2024 | 129266 | 0.290 |
Why?
| | Maternal Nutritional Physiological Phenomena | 3 | 2018 | 169 | 0.290 |
Why?
| | Infant, Newborn | 5 | 2024 | 5736 | 0.290 |
Why?
| | Proteins | 1 | 2013 | 941 | 0.290 |
Why?
| | Pregnancy | 8 | 2020 | 6390 | 0.270 |
Why?
| | Mutation | 2 | 2018 | 3710 | 0.270 |
Why?
| | Fetus | 3 | 2020 | 770 | 0.260 |
Why?
| | Female | 19 | 2020 | 68551 | 0.250 |
Why?
| | Glycosylation | 2 | 2023 | 152 | 0.240 |
Why?
| | Dichloroacetic Acid | 1 | 2024 | 8 | 0.230 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.220 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 25 | 0.220 |
Why?
| | Niacinamide | 1 | 2024 | 75 | 0.220 |
Why?
| | Keto Acids | 1 | 2023 | 13 | 0.210 |
Why?
| | HLA-DRB1 Chains | 2 | 2015 | 108 | 0.210 |
Why?
| | Siblings | 1 | 2023 | 215 | 0.200 |
Why?
| | Glycolysis | 1 | 2024 | 311 | 0.200 |
Why?
| | Pregnancy Complications | 2 | 2018 | 493 | 0.190 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 13 | 0.190 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2018 | 574 | 0.190 |
Why?
| | HLA-B8 Antigen | 2 | 2012 | 14 | 0.190 |
Why?
| | Lactic Acid | 1 | 2023 | 298 | 0.190 |
Why?
| | Mutation, Missense | 1 | 2023 | 317 | 0.180 |
Why?
| | Metabolism | 1 | 2021 | 38 | 0.180 |
Why?
| | Genotype | 5 | 2015 | 1835 | 0.180 |
Why?
| | Metabolome | 1 | 2024 | 338 | 0.180 |
Why?
| | Ischemia | 1 | 2024 | 406 | 0.180 |
Why?
| | Sheep | 2 | 2020 | 838 | 0.180 |
Why?
| | Propionic Acidemia | 1 | 2020 | 3 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 340 | 0.170 |
Why?
| | Leucine | 1 | 2020 | 108 | 0.170 |
Why?
| | False Positive Reactions | 1 | 2020 | 114 | 0.170 |
Why?
| | Disease Progression | 2 | 2020 | 2630 | 0.160 |
Why?
| | Colorado | 2 | 2020 | 4406 | 0.150 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2018 | 36 | 0.150 |
Why?
| | Dystroglycans | 1 | 2018 | 5 | 0.150 |
Why?
| | Glucose | 2 | 2021 | 1001 | 0.150 |
Why?
| | Qb-SNARE Proteins | 1 | 2018 | 6 | 0.150 |
Why?
| | Leptin | 2 | 2018 | 219 | 0.150 |
Why?
| | Insulin | 3 | 2018 | 2325 | 0.150 |
Why?
| | Placental Insufficiency | 1 | 2019 | 112 | 0.150 |
Why?
| | Adult | 9 | 2020 | 35495 | 0.150 |
Why?
| | Muscular Dystrophies | 1 | 2018 | 35 | 0.150 |
Why?
| | Preconception Care | 1 | 2018 | 41 | 0.150 |
Why?
| | Enteral Nutrition | 1 | 2020 | 188 | 0.150 |
Why?
| | Micronutrients | 1 | 2018 | 88 | 0.140 |
Why?
| | Lipids | 2 | 2021 | 625 | 0.140 |
Why?
| | Muscle Cells | 1 | 2017 | 42 | 0.140 |
Why?
| | Vesicular Transport Proteins | 1 | 2018 | 84 | 0.140 |
Why?
| | Electron Transport | 1 | 2017 | 112 | 0.140 |
Why?
| | Maternal-Fetal Exchange | 1 | 2018 | 161 | 0.140 |
Why?
| | Autoimmune Diseases | 2 | 2011 | 426 | 0.140 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 90 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2020 | 523 | 0.130 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2016 | 14 | 0.130 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2016 | 7 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 333 | 0.130 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2015 | 15 | 0.120 |
Why?
| | Oxidation-Reduction | 2 | 2020 | 1028 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 126 | 0.120 |
Why?
| | Retinal Diseases | 1 | 2016 | 86 | 0.120 |
Why?
| | Lower Extremity | 1 | 2019 | 404 | 0.120 |
Why?
| | Adipogenesis | 1 | 2015 | 50 | 0.120 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2015 | 79 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2015 | 2063 | 0.120 |
Why?
| | Fetal Development | 1 | 2018 | 288 | 0.120 |
Why?
| | Pediatric Obesity | 2 | 2020 | 571 | 0.120 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 84 | 0.120 |
Why?
| | Body Mass Index | 3 | 2018 | 2272 | 0.120 |
Why?
| | Alleles | 3 | 2015 | 845 | 0.120 |
Why?
| | PPAR gamma | 1 | 2015 | 183 | 0.110 |
Why?
| | Postprandial Period | 1 | 2015 | 104 | 0.110 |
Why?
| | Milk, Human | 1 | 2016 | 151 | 0.110 |
Why?
| | Oxidoreductases | 1 | 2014 | 92 | 0.110 |
Why?
| | Risk Factors | 3 | 2018 | 9745 | 0.110 |
Why?
| | Phenotype | 2 | 2014 | 3074 | 0.110 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4057 | 0.110 |
Why?
| | South Africa | 1 | 2014 | 192 | 0.110 |
Why?
| | beta Catenin | 1 | 2015 | 223 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 616 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2015 | 239 | 0.110 |
Why?
| | Animals | 5 | 2024 | 35309 | 0.110 |
Why?
| | Genetic Loci | 1 | 2015 | 275 | 0.110 |
Why?
| | Atrophy | 1 | 2013 | 171 | 0.100 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2715 | 0.100 |
Why?
| | Cell Differentiation | 2 | 2017 | 1887 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2013 | 299 | 0.100 |
Why?
| | Child, Preschool | 2 | 2020 | 10459 | 0.100 |
Why?
| | Renin | 1 | 2012 | 32 | 0.100 |
Why?
| | HLA-DR4 Antigen | 1 | 2012 | 78 | 0.100 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2012 | 133 | 0.090 |
Why?
| | Mitochondrial Proteins | 1 | 2013 | 248 | 0.090 |
Why?
| | Mitochondria | 1 | 2017 | 877 | 0.090 |
Why?
| | Hypoxia | 1 | 2018 | 1084 | 0.090 |
Why?
| | Brain | 2 | 2020 | 2669 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1688 | 0.090 |
Why?
| | Dosage Compensation, Genetic | 1 | 2010 | 12 | 0.090 |
Why?
| | Major Histocompatibility Complex | 1 | 2011 | 230 | 0.090 |
Why?
| | HLA-DQ Antigens | 1 | 2011 | 179 | 0.090 |
Why?
| | Microarray Analysis | 1 | 2010 | 117 | 0.090 |
Why?
| | Child | 4 | 2021 | 20785 | 0.080 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 223 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1165 | 0.080 |
Why?
| | Hydrocortisone | 1 | 2012 | 306 | 0.080 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 257 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2499 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2010 | 313 | 0.080 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 385 | 0.080 |
Why?
| | Pedigree | 1 | 2010 | 486 | 0.080 |
Why?
| | Gene Frequency | 1 | 2010 | 502 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2016 | 640 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2020 | 10202 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 639 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2537 | 0.070 |
Why?
| | Proteomics | 2 | 2024 | 1054 | 0.070 |
Why?
| | Risk | 1 | 2010 | 854 | 0.070 |
Why?
| | Developmental Disabilities | 1 | 2010 | 261 | 0.070 |
Why?
| | Mice | 1 | 2024 | 16915 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1949 | 0.070 |
Why?
| | Adolescent | 3 | 2015 | 20313 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2740 | 0.060 |
Why?
| | Time Factors | 2 | 2016 | 6543 | 0.060 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2024 | 10 | 0.060 |
Why?
| | Prognosis | 1 | 2012 | 3773 | 0.050 |
Why?
| | Introns | 1 | 2024 | 251 | 0.050 |
Why?
| | Young Adult | 3 | 2018 | 12391 | 0.050 |
Why?
| | Genetic Association Studies | 2 | 2015 | 361 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 330 | 0.050 |
Why?
| | Follow-Up Studies | 1 | 2012 | 4887 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2020 | 14461 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 5050 | 0.050 |
Why?
| | Echocardiography | 1 | 2024 | 629 | 0.040 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 36 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 141 | 0.040 |
Why?
| | Vitamins | 1 | 2021 | 173 | 0.040 |
Why?
| | Drug Synergism | 1 | 2020 | 370 | 0.040 |
Why?
| | Hindlimb | 1 | 2019 | 122 | 0.040 |
Why?
| | Alanine | 1 | 2019 | 142 | 0.040 |
Why?
| | Macaca | 1 | 2018 | 54 | 0.040 |
Why?
| | Critical Illness | 1 | 2024 | 757 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 2018 | 54 | 0.040 |
Why?
| | Gluconeogenesis | 1 | 2018 | 76 | 0.040 |
Why?
| | Diet, Western | 1 | 2018 | 79 | 0.040 |
Why?
| | Muscle Proteins | 1 | 2019 | 220 | 0.040 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2018 | 97 | 0.040 |
Why?
| | United States | 1 | 2014 | 13826 | 0.030 |
Why?
| | Guatemala | 1 | 2018 | 313 | 0.030 |
Why?
| | Adiponectin | 1 | 2018 | 235 | 0.030 |
Why?
| | Fundus Oculi | 1 | 2016 | 61 | 0.030 |
Why?
| | Lactobacillales | 1 | 2016 | 5 | 0.030 |
Why?
| | Middle Aged | 2 | 2015 | 31090 | 0.030 |
Why?
| | Gammaproteobacteria | 1 | 2016 | 12 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2016 | 59 | 0.030 |
Why?
| | Pyruvate Kinase | 1 | 2016 | 26 | 0.030 |
Why?
| | Triglycerides | 1 | 2018 | 527 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 636 | 0.030 |
Why?
| | Plethysmography | 1 | 2016 | 107 | 0.030 |
Why?
| | Fatty Acids, Volatile | 1 | 2016 | 57 | 0.030 |
Why?
| | Iodide Peroxidase | 1 | 2015 | 28 | 0.030 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2015 | 18 | 0.030 |
Why?
| | Remission Induction | 1 | 2016 | 271 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2015 | 68 | 0.030 |
Why?
| | Cohort Studies | 2 | 2016 | 5409 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2015 | 46 | 0.030 |
Why?
| | Iron-Binding Proteins | 1 | 2015 | 40 | 0.030 |
Why?
| | Pancreatitis | 1 | 2016 | 129 | 0.030 |
Why?
| | Umbilical Cord | 1 | 2015 | 83 | 0.030 |
Why?
| | CTLA-4 Antigen | 1 | 2015 | 87 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 874 | 0.030 |
Why?
| | Muscle Development | 1 | 2015 | 103 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2020 | 789 | 0.030 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 550 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 819 | 0.030 |
Why?
| | Feces | 1 | 2016 | 441 | 0.030 |
Why?
| | Autoantigens | 1 | 2015 | 419 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1497 | 0.020 |
Why?
| | Breast Feeding | 1 | 2016 | 423 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 649 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4077 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 4926 | 0.020 |
Why?
|
|
Baker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|